Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4

Biochemical and Biophysical Research Communications

Volumn 350, Issue 4, 2006, Pages 866-871

  Youn, Hyung S ^a   Lee, Joo Y ^b   Saitoh, Shin I ^c   Miyake, Kensuke ^c   Hwang, Daniel H ^a  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Auranofin; COX 2; Dimerization; Gold; IKK ; LPS; MyD88; NF B; Toll like receptor; TRIF

Indexed keywords

ANTIRHEUMATIC AGENT; AURANOFIN; CYCLOOXYGENASE 2; GOLD COMPLEX; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR; TRIF PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIMERIZATION; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIRHEUMATIC AGENTS; AURANOFIN; B-LYMPHOCYTES; CELL LINE; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GOLD; LIPOPOLYSACCHARIDES; MICE; TOLL-LIKE RECEPTOR 4;

EID: 33751011612     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.09.097     Document Type: Article

References (33)

1. Takeda K., and Akira S. Toll-like receptors in innate immunity. Int. Immunol. 17 (2005) 1-14
2. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1 (2001) 135-145
3. O'Neill L.A. TLRs: Professor Mechnikov, sit on your hat. Trends Immunol. 25 (2004) 687-693
4. Vogel S.N., Fitzgerald K.A., and Fenton M.J. TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. Mol. Interv. 3 (2003) 466-477
5. Rhee S.H., and Hwang D. Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. J. Biol. Chem. 275 (2000) 34035-34040
6. Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., Golenbock D.T., Coyle A.J., Liao S.M., and Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4 (2003) 491-496
7. Toshchakov V., Jones B.W., Perera P.Y., Thomas K., Cody M.J., Zhang S., Williams B.R., Major J., Hamilton T.A., Fenton M.J., and Vogel S.N. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat. Immunol. 3 (2002) 392-398
8. Meylan E., Burns K., Hofmann K., Blancheteau V., Martinon F., Kelliher M., and Tschopp J. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat. Immunol. 5 (2004) 503-507
9. Kawai T., and Akira S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17 (2005) 338-344
10. Andreakos E., Sacre S., Foxwell B.M., and Feldmann M. The toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritis. Front. Biosci. 10 (2005) 2478-2488
11. Simon L.S. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments. Int. J. Clin. Pract. 54 (2000) 243-249
12. Andreakos E.T., Foxwell B.M., Brennan F.M., Maini R.N., and Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. 13 (2002) 299-313
13. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14 (1996) 397-440
14. Stern I., Wataha J.C., Lewis J.B., Messer R.L., Lockwood P.E., and Tseng W.Y. Anti-rheumatic gold compounds as sublethal modulators of monocytic LPS-induced cytokine secretion. Toxicol. In Vitro 19 (2005) 365-371
15. Yanni G., Nabil M., Farahat M.R., Poston R.N., and Panayi G.S. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann. Rheum. Dis. 53 (1994) 315-322
16. Bondeson J., and Sundler R. Auranofin inhibits the induction of interleukin 1 beta and tumor necrosis factor alpha mRNA in macrophages. Biochem. Pharmacol. 50 (1995) 1753-1759
17. Williams D.H., Jeffery L.J., and Murray E.J. Aurothioglucose inhibits induced NF-κB and AP-1 activity by acting as an IL-1 functional antagonist. Biochim. Biophys. Acta 1180 (1992) 9-14
18. Yang J.P., Merin J.P., Nakano T., Kato T., Kitade Y., and Okamoto T. Inhibition of the DNA-binding activity of NF-kappa B by gold compounds in vitro. FEBS Lett. 361 (1995) 89-96
19. Saitoh S., Akashi S., Yamada T., Tanimura N., Kobayashi M., Konno K., Matsumoto F., Fukase K., Kusumoto S., Nagai Y., Kusumoto Y., Kosugi A., and Miyake K. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int. Immunol. 16 (2004) 961-969
20. Lee J.Y., Zhao L., Youn H.S., Weatherill A.R., Tapping R., Feng L., Lee W.H., Fitzgerald K.A., and Hwang D.H. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J. Biol. Chem. 279 (2004) 16971-16979
21. Lee J.Y., Ye J., Gao Z., Youn H.S., Lee W.H., Zhao L., Sizemore N., and Hwang D.H. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J. Biol. Chem. 278 (2003) 37041-37051
22. Youn H.S., Saitoh S.I., Miyake K., and Hwang D.H. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem. Pharmacol. 72 (2006) 62-69
23. Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., Golenbock D.T., Coyle A.J., Liao S.M., and Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4 (2003) 491-496
24. Kyo F., Futani H., Matsui K., Terada M., Adachi K., Nagata K., Sano H., Tateishi H., Tsutsui H., and Nakanishi K. Endogenous interleukin-6, but not tumor necrosis factor alpha, contributes to the development of toll-like receptor 4/myeloid differentiation factor 88-mediated acute arthritis in mice. Arthritis Rheum. 52 (2005) 2530-2540
25. Roelofs M.F., Boelens W.C., Joosten L.A., Abdollahi-Roodsaz S., Geurts J., Wunderink L.U., Schreurs B.W., van den Berg W.B., and Radstake T.R. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J. Immunol. 176 (2006) 7021-7027
26. Sutmuller R.P., den Brok M.H., Kramer M., Bennink E.J., Toonen L.W., Kullberg B.J., Joosten L.A., Akira S., Netea M.G., and Adema G.J. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 116 (2006) 485-494
27. Jeon K.I., Byun M.S., and Jue D.M. Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp. Mol. Med. 35 (2003) 61-66
28. Handel M.L., Watts C.K., deFazio A., Day R.O., and Sutherland R.L. Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos. Proc. Natl. Acad. Sci. USA 92 (1995) 4497-4501
29. Tao X., Xu Y., Zheng Y., Beg A.A., and Tong L. An extensively associated dimer in the structure of the C713S mutant of the TIR domain of human TLR2. Biochem. Biophys. Res. Commun. 299 (2002) 216-221
30. Covert M.W., Leung T.H., Gaston J.E., and Baltimore D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 309 (2005) 1854-1857
31. Jeon K.I., Jeong J.Y., and Jue D.M. Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J. Immunol. 164 (2000) 5981-5989
32. Yamashita M., Ashino S., Oshima Y., Kawamura S., Ohuchi K., and Takayanagi M. Inhibition of TPA-induced NF-kappaB nuclear translocation and production of NO and PGE2 by the anti-rheumatic gold compounds. J. Pharm. Pharmacol. 55 (2003) 245-251
33. Bratt J., Belcher J., Vercellotti G.M., and Palmblad J. Effects of anti-rheumatic gold salts on NF-kappa B mobilization and tumour necrosis factor-alpha (TNF-alpha)-induced neutrophil-dependent cytotoxicity for human endothelial cells. Clin. Exp. Immunol. 120 (2000) 79-84